# Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

> **NCT03798054** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 878 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine/Lixisenatide (HOE901/AVE0010)
- **DRUG:** Insulin glargine (HOE901)
- **DRUG:** Lixisenatide (AVE0010)
- **DRUG:** Metformin
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT03798054
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 878 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798054, "Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03798054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*